Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
C1 esterase inhibitor (C1-INH) is a serine protease inhibitor (serpin) that plays a critical role in regulating the complement system, contact system, and coagulation/fibrinolytic pathways. It inhibits the activation of the classical complement pathway by binding to and inactivating proteases such as C1r and C1s. C1-INH also regulates the contact system by inhibiting plasma kallikrein, factor XIIa, and factor XIa. Deficiency or dysfunction of C1-INH leads to unchecked complement activation and increased bradykinin levels, resulting in conditions like hereditary angioedema (HAE).
Irreversibly binds to and inhibits target proteases (C1s, kallikrein, factor XIIa/XIa), preventing their enzymatic activity and downstream effects like bradykinin production and complement activation.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on C1 esterase inhibitor (C1-INH).